Payment overview · 2025
General Payments
$733.83
36 reported records · 17 companies
Healthcare provider profile · identity verified
Nancy P Schenk, MD
Allopathic & Osteopathic Physicians|Family Medicine · DAKOTA DUNES, SD · NPI 1467413971
Verified facts
What the public records show
CMS Open Payments records show Nancy P Schenk, MD received $733.83 in general payments during 2025 across 36 reported records.
Astellas Pharma US Inc accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $149.05 | 20.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.62 | 12.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.06 | 11.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.99 | 9.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.06 | 5.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.76 | 5.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.42 | 5.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.92 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.92 | 4.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.36 | 3.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.64 | 3.5% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.30 | 3.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $22.89 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.16 | 2.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $15.74 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.84 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.10 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $648.84 | 35 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $94.62 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.62 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.06 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.53 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.50 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.42 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 117 |
| Omeprazole | Omeprazole | 401 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 102 |
| Losartan Potassium | Losartan Potassium | 363 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 81 |
| Lisinopril | Lisinopril | 239 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 184 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 39 |
| Gabapentin | Gabapentin | 150 | 39 |
| Potassium Chloride | Potassium Chloride | 149 | 35 |
| Metformin Hcl | Metformin Hcl | 133 | 32 |
| Metformin Hcl Er | Metformin Hcl | 131 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 41 |
| Trazodone Hcl | Trazodone Hcl | 126 | 30 |
| Furosemide | Furosemide | 121 | 33 |
| Sertraline Hcl | Sertraline Hcl | 121 | 36 |
| Simvastatin | Simvastatin | 111 | 27 |
| Allopurinol | Allopurinol | 103 | 26 |
| Ozempic | Semaglutide | 102 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 38 |
| Montelukast Sodium | Montelukast Sodium | 97 | 28 |
| Tramadol Hcl | Tramadol Hcl | 96 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 44 |
| Spironolactone | Spironolactone | 92 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 23 |
| Eliquis | Apixaban | 89 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 21 |
| Alprazolam | Alprazolam | 82 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 22 |
| Ezetimibe | Ezetimibe | 79 | 16 |
| Memantine Hcl | Memantine Hcl | 77 | suppressed |
| Carvedilol | Carvedilol | 72 | 16 |
| Lorazepam | Lorazepam | 72 | 26 |
| Alendronate Sodium | Alendronate Sodium | 69 | 20 |
| Prednisone | Prednisone | 69 | 54 |
| Synthroid | Levothyroxine Sodium | 61 | 12 |
| Bupropion Xl | Bupropion Hcl | 59 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 14 |
| Meloxicam | Meloxicam | 50 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Lactulose | Lactulose | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 15 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 14 |
| Celecoxib | Celecoxib | 35 | 16 |
| Estradiol | Estradiol | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 20 |
| Azithromycin | Azithromycin | 28 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 17 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Naproxen | Naproxen | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $733.83 · 36 records | Astellas Pharma US Inc | ABRYSVO, AUSTEDO XR, Andembry, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, GOMEKLI, Kerendia, OPSUMIT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SYMPLICITY G3, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VOQUEZNA, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error